Mallinckrodt Pharmaceuticals and Endo are in talks over a potential merger worth about $7 billion, according to a report from ...

Can Gilead be held accountable for holding back the sale of an HIV drug it allegedly knew was safer than its blockbuster predecessor? The answer could offer a unique example of a situation where a ...

Ascletis' ASC47 shows 1.7% weight loss vs. placebo in Phase 1b trial, Vivace gets a $35M Series D for VT3989, and Harbour BioMed launches obesity startup Élancé Therapeutics.

Viking Therapeutics has contracted CDMO CordenPharma for a total of $150 million to make billions of clinical and commercial doses of its GLP-1/GIP receptor agonist for weight loss.

Trump admin's FDA medical product review units remain protected from cuts, while Marty Makary awaits confirmation as ...

Unlocking manufacturing capacity will be key for Legend Biotech and Johnson and Johnson in achieving their goal of reaching ...

Ono Pharmaceuticals is spending $280 million upfront to take the global rights of Ionis Pharmaceuticals’ asset for a rare ...

Merck convinced a federal judge to toss claims alleging that it failed to properly warn patients of potential risks related ...

Gilead said two experimental once-a-year versions of its HIV prevention shot lenacapavir passed muster in an early-stage ...

Merck has opened a new vaccine manufacturing plant at its existing site in Durham, NC, which will make a shot that is an ...

After months of reports that Walgreens was looking to go private, the retail pharmacy giant (to some folks’ surprise) managed to pull off a deal. The $10 billion transaction with Sycamore Partners, ...

Mineralys Therapeutics plans $250M share offering after lorundrostat's Phase 3 success; Coherus cuts 30% staff; BioNTech's melanoma trial fails ...